RAPS recognizes that the current situation in Ukraine impacts our members and customers on many levels. If you are directly impacted by the current situation in the region and are challenged to meet your deadlines or obligations to RAPS, please reach out to raps@raps.org so that we can defer those challenges. Your health and safety are paramount to us.

Regulatory Focus™ > News Articles > Regulatory Aspects of Pharma Business in Asia

Regulatory Aspects of Pharma Business in Asia

Posted 01 February 2009

Asian countries have for some time experienced a high overall growth rate. As a result, local populations have benefited from increased per capita spending power and growth of the middle class, which have led to demands for improved access to better healthcare and pharmaceuticals. According to a recent report from IMS Health, the global market for medications reached $712 billion (US) last year, up by $178 billion over the previous five years. But the rate of growth is slowing-6.4% in 2007 compared to 11.8% in 2001. Without the bigger economies in Asia, that figure would be lower still; China, South Korea, and India grew by 25.7%, 10.7%, and 13% respectively.1


© 2022 Regulatory Affairs Professionals Society.